

## Science Translation and Innovative Research (STAIR™) and Data, Informatics & Application Launch (DIAL™) Grant Programs: Funding Partners (FY 2020-21)

---

Venture Catalyst has engaged several campus and industry partners to expand support and potential funding available to particular technologies and projects through the STAIR and DIAL Grant programs. We may announce additional partners before the application deadlines. Please check the proof-of-concept programs [web site](#) for updates or [contact us](#) for more information.

### **Campus Partners**

PIs from partner Colleges / Schools are eligible for additional support if their proposal is selected for an award through the regular review process

Supplements will be 50% of the awarded budget and can be used for graduate student, post-docs, or staff salary support or other expenses.

Colleges / Schools will work with awardees and assigned STAIR Grant mentors to create modified budgets that best support projects.

*The following partners have each made up to  
\$25,000 of supplemental funding available:*



*The following partners have each made up to  
\$50,000 of supplemental funding available:*



### **Industry Partners**

Partner companies will consider supporting proposal for successful projects in their identified areas of interest.

PIs who believe that their proposal falls within the partner company's scope should indicate their interest in being considered in the Project Abstract section of the online project application.

If a partner company selects a PI's proposal for consideration, it will work with the awardee and assigned STAIR Grant mentors to create modified budgets that best support projects



*See areas of  
interest below*

<b>Bayer Areas of Interest</b>	
<b>HealthCare</b>	<b>Crop Science Division</b>
Therapeutics, adjacencies, and supporting technologies in: <ul style="list-style-type: none"> <li>• Cardiovascular               <ul style="list-style-type: none"> <li>○ Heart Diseases</li> <li>○ Vascular Diseases</li> <li>○ Lung Diseases</li> <li>○ Kidney Diseases</li> <li>○ Acute Organ Disorders</li> </ul> </li> <li>• Oncology               <ul style="list-style-type: none"> <li>○ Oncogenic Signaling</li> <li>○ Targeted Alpha Therapies</li> <li>○ Immuno-Oncology</li> </ul> </li> <li>• Women’s Health               <ul style="list-style-type: none"> <li>○ Uterine Fibroids</li> <li>○ Polycystic Ovary Syndrome</li> <li>○ Endometriosis</li> </ul> </li> </ul>	Novel crop protection traits, chemistries, and biological control products  Enabling technologies for genome editing and engineering, disease and pest detection, improvement of agronomic practices and pesticide residue detection  Formulations for crop protection chemistries and biological products  Imaging technologies and data science predictive analytics tools
Cell and gene therapy platforms and approaches	

# ELANCO ANIMAL HEALTH

At Elanco(NYSE: ELAN), we provide those who raise and care for animals with solutions that empower them to advance a vision of food and companionship enriching life.

We understand the powerful role healthy animals play in making lives better. As pets increasingly become important parts of our families, so too does the need to help them live longer, healthier, higher-quality lives. As the global population grows, so too will the need to meet the demand for safe, affordable food for all.

Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. We strive to develop and deliver products safe for consumers, animals and the environment through innovation and a shared vision to enrich the lives of people worldwide.

## External Innovation:

Elanco's partnership engine providing rapid evaluation of external opportunities for both Companion and Food Animals.

## Benefits of partnering with Elanco:

- Global presence in food animal and companion animal markets
- Cross species disease research
- Significant sales and marketing capabilities in health and nutrition
- Extensive R&D capabilities with an innovative pipeline and approach
- Create alternative revenue streams and discover unrealized commercial value



### Animal Health Licensing:

- Potentially faster route to market/income to support additional development efforts
- Rapid proof of concept in the target species
- Opportunities that fail in human health may become successful animal health products through re-purposing and may provide extended patent life

### Food and Companionship Enriching Life Focused R&D Efforts

Platform	Large Molecules	Vaccines	Small Molecules	Nutritional Health
Species	<b>Food Animal</b> Cattle Swine Poultry Fish		<b>Companion Animal</b> Dogs Cats	
Unmet Needs	<b>Respiratory</b> <b>Enteric/Gut Health</b> <b>Mastitis</b> <b>Metabolic</b> <b>Parasiticide</b>		<b>Parasiticide</b> <b>Dermatology</b> <b>Pain/Osteoarthritis</b> <b>Cardiovascular</b> <b>Diabetes</b>	
Ancillary Areas of Focus	<b>Reproduction</b> <b>Milk Production</b>		<b>Oncology</b> <b>CKD</b> <b>IBD</b>	

**HAVE AN IDEA?**

**COLLABORATE WITH US.**

▶ [ExternalInnovation@Elanco.com](mailto:ExternalInnovation@Elanco.com)